CMPD-1

Modify Date: 2025-08-24 20:16:39

Use of CMPD-1

CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Kiapp) of 330 nM[1][2].

Name	4-[4-(2-fluorophenyl)phenyl]-N-(4-hydroxyphenyl)butanamide
Synonym	More Synonyms

Description	CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent Ki (Kiapp) of 330 nM[1][2].
Related Catalog	Signaling Pathways >> MAPK/ERK Pathway >> MAPKAPK2 (MK2) Research Areas >> Cancer
Target	Kiapp: 330 nM (MK2 phosphorylation)[2]
In Vitro	CMPD1 does not inhibit p38 MAPK-mediated phosphorylation of other two substrates, MBP and ATF2[1].
References	[1]. Gurgis F, et al. Cytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2. Cell Death Discov. 2015 Sep 7;1:15028. [2]. Davidson W, er al. Discovery and characterization of a substrate selective p38alpha inhibitor. Biochemistry. 2004 Sep 21;43(37):11658-71.

N/A

CAS#:40096-53-5

4-Aminophenol

CAS#:123-30-8

~14%

CMPD-1

CAS#:41179-33-3

Precursor 1
CAS#:123-30-8 4-Aminophenol
DownStream 0

CMPD1

MK2a Inhibitor

Mitogen-activated protein kinase-activated protein kinase 2a Inhibitor

MAPKAPK2a Inhibitor